STATEMENT OF TRANSLATIONAL RELEVANCE
Targeted therapy has made success in melanoma treatment. However, these validated targets have not benefited all melanoma patients, leaving more than 50% of melanoma patients without proper targets for targeted therapy. Mammalian target of rapamycin (mTOR) has been the key targets for cancer treatment. Unfortunately, clinical trials using mTOR inhibitors have not reached significant improvements of survivals in advanced melanoma patients. We set out to examine the gene aberrations of mTOR in 412 melanoma patients, and found that 43 (10.4%) of them were identified to contain nonsynonymous mTOR mutations. mTOR nonsynonymous mutations are frequent in acral and mucosal melanomas (11.0% and 14.3%, respectively). Gain-of-function mutations of mTOR exist, and are responsive to targeted therapy inhibitors. Our study has greatly improved the understanding of mTOR nonsynonymous mutation status in melanoma, and indicates that selection of patients bearing these active mTOR mutations may be a better strategy to conduct future clinical trials. 
INTRODUCTION
Malignant melanoma is one of the most aggressive cancers with extremely poor prognosis, and the median survival time for patients with stage IV disease is about 6 to 8 months (1) (2) (3) . Individualized targeted therapy has achieved successes in melanoma treatment. Among these targets, BRAF and C-KIT are the most attractive (4) (5) (6) . BRAF and C-KIT inhibitors have been recommended as the first line of therapy by National Comprehensive Cancer Network in Melanoma Treatment Guidelines (2013 edition) for advanced melanoma patients with corresponding genetic mutations (7) . The frequency of BRAF and CKIT mutation in Chinese melanoma patients is about 25.5% and 10.8% (8, 9), respectively, thus leaving more than 50% of Chinese melanoma patients without validated targets for targeted therapy.
Mammalian target of rapamycin (mTOR) is a serine and threonine protein kinase and plays crucial roles in transcriptional regulation, initiation of protein synthesis, ribosome biogenesis, metabolism and apoptosis etc. after being activated by various factors (10) (11) (12) . mTOR signaling pathway has been the key targets for cancer treatment (13) (14) (15) . Inhibitors for mTOR, including rapamycin and the derivatives RAD001, CCI-779 and AP23573, usually bind FKBP12, inhibit tumor growth and even induce apoptosis (16) (17) (18) (19) . Unfortunately, clinical trials using mTOR inhibitors in melanoma patients are not successful. A phase II clinical trial using RAD001 in 24 cases of metastatic melanoma showed that the median progression-free survival (PFS) was about 3 months (20) . Another phase II clinical trial using RAD001 in combination with temozolomide in 48 patients with advanced stage-IV unresectable melanomas showed that the median PFS was only 2.4 months (21) . Genetic selection of specific target may be useful for the establishment of therapeutic strategy for advanced melanoma patients. The two clinical trials using mTOR inhibitors have not screened the genetic mTOR nonsynonymous mutations (termed as mutation in this study if not specified) in the melanoma patients (20, 21) .
Therefore, it remains to be determined whether melanoma patients bearing certain genetic mutations in mTOR will respond better to mTOR inhibitors.
Genetic aberrations of mTOR have not been extensively investigated. Data from the TCGA and COSMIC (until Sep. 2015) suggested that the frequency of mTOR nonsynonymous mutations in all the cancers is about 1.86% to 3.00%, and it is about 3.61% to 7.19% in cutaneous melanomas (22, 23) . These databases mainly include the data derived from Caucasian melanoma patients, which had not been validated in larger cohorts of melanoma samples (24-26). More importantly, large-scale screening of mTOR aberrations in clinical samples has not been reported.
We collected 412 melanoma tissue samples from melanoma patients, and examined all samples for aberrations in all the 58 exons of mTOR gene. This study represents the first systematic analysis of somatic mTOR mutations in melanoma patients. Kinase activities of these mutated mTOR as well as their sensitivity to PI3K-AKT-mTOR pathway inhibitors were evaluated.
Research. 
MATERIALS AND METHODS

Patients and tissue samples
This study involved samples from primary lesions of 412 melanoma patients, 
DNA preparation and mutation screening
Genomic DNA was extracted from formalin-fixed, paraffin-embedded sections using a QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany). To detect DNA sequence aberrations, we amplified exons 1 to 58 of the mTOR gene by PCR in at least two separate preparations of genomic DNA. The primer sequences are listed in Supplementary Table S1 . We purified PCR products with QIAquick (Qiagen), and directly sequenced them using Big Dye Terminator sequencing chemistry on an ABI3130 automated sequencer (Applied Biosystems, Foster City, CA). All
Immunohistochemistry
Immunohistochemical (IHC) analyses were performed using antibodies against phospho-AKT (Ser473), phospho-mTOR (Ser2448), phospho-S6RP (Ser235/236) and phospho-4EBP1 (Thr37/46) (Cell Signaling Technology, Beverly, MA) as described (4, 8) . The staining score for each sample, counting the intensity and density of the staining, was graded as 0, 1, 2, and 3 ("0" as negative, and "3" as the strongest; or "0" as negative, and "1", "2" and "3" as positive) by three pathologists independently (typical staining was shown in Supplementary Fig. S1 ), without the knowledge of mTOR mutation status of these patients.
Plasmid construction
A mammalian expression vector (pCMV6) containing the human wild-type mTOR cDNA with Flag tag at the C-terminal was obtained from Sino Biologicol, Inc.
(Beijing, China). All the mTOR mutants were generated by site-directed mutagenesis.
S2215Y mutant of mTOR was used as a positive gain-of-function control (27) . Additionally, the cells also were authenticated to show characteristics of HEK293 cells, including epithelial phenotype, hypotriploidy of chromosome, and the typical chromosome markers (such as der (1)t(1;15) (q42; q13), der(19)t(3;19)(q12; q13), der(12)t(8;12) (q22; p13) and paired der(1) and M8 (or Xq + )). 
Immunoprecipitation and Western blotting
Statistical analyses
Statistical analyses were performed using SPSS 16.0 software. Continuous data such as age and thickness were described using means ± SD for normally distributed data.
The correlations between mutational status and clinical parameters were evaluated by Chi-square test or Fisher's exact test. Kaplan-Meier estimates of time-to-event overall survival (OS) were calculated. Log-rank tests were used to estimate the statistical significance between the time-dependent outcomes of OS. Cox proportional-hazards regression analysis was conducted to estimate the Hazard Ratio (HR) for OS. All statistical analyses were two sided, and P < 0.05 was considered as statistically significant.
RESULTS
mTOR gene aberrations in melanoma
Of the 412 melanoma samples analyzed, 43 (10.4%) of them were identified to contain nonsynonymous mTOR mutations. The mutation frequencies of mTOR in acral, mucosal, melanomas on skin with chronic sun-induced damage (CSD), melanomas on skin without chronic sun-induced damage (non-CSD) melanoma and unknown primary subtypes were 11.0%, 14.3%, 6.7%, 3.4% and 11.1%, respectively ( Table 1) . The nonsynonymous mutation frequency of mTOR in acral and mucosal melanoma (38/315, 12.1%) tends to be higher than that in other melanoma (5/97, 5.2%) (P = 0.052). Surprisingly, synonymous aberrations were detected in all the melanomas ( Supplementary Table S2 ), which may indicate that the exon regions of mTOR were rather unstable and varied at high frequency. Since these synonymous aberrations were unrelated to the analysis of sensitivity to PI3K-AKT-mTOR inhibitors, though most of them had not been deposited in COSMIC database, they were not further evaluated in this study. nonsynonymous mutations did not cluster defined hotspots. However, 6 recurrent mTOR mutations were found: P1128L (2 cases), V1275A (2 cases), C1303R (2 cases), A1836T (2 cases), G1914A (2 cases) and 5490-5501 base pair deletion (TGCCGCCACCAC, 2 cases) (Fig. 1B and Supplementary Table S2 ).
We detected nonsynonymous mTOR mutations in 25 of 58 exons, which NRAS mutation in patients of our cohort showed that mutation frequency of these genes did not significantly differ between patients with or without mTOR mutation ( Table 2) . Therefore mTOR mutation may be unrelated to the other mutations such as CKIT, BRAF and NRAS mutation.
Correlation of mTOR mutation to clinicopathologic features
In our cohort, the mean age, gender, average thickness, ulceration rate, primary sites and clinical stages of melanomas or patients were all not significantly different between melanomas or patients with or without mTOR nonsynonymous mutations ( Table 2 ). These data indicate that mTOR mutation may be unrelated to these clinical features of melanomas.
Then we analyzed the prognostic significance of mTOR nonsynonymous mutation for OS. The survival data were collected for patients (n = 392) who were diagnosed as primary melanoma or melanoma of unknown primary site
Research. Table S2 ). The median follow-up period was 31.0 (range: 3.0-300.0) months. We found that the median survival time for patients with mTOR mutations (43.1 months, 95% CI: 34.8-51.8 months) was significantly shorter than that for patients without nonsynonymous mTOR mutations (81.3 months, 95% CI: 60.2-102.4 months; P = 0.028; Supplementary Fig. S2) . In univariate Cox analysis, we found that the hazard ratio (HR) for patients bearing mTOR nonsynonymous mutation was 0.645 (95% CI: 0.43-0.96; P = 0.031). Therefore, mTOR mutation, together with thickness, ulceration status and TNM stage, may be of prognostic significance for melanoma patients, and melanoma patients with mTOR mutations may show higher risk of death ( Table 3) . For multivariate Cox regression assay, we excluded the variate thickness since the data for 118 patients (most of them had mucosal melanoma or melanoma with the primary site unknown). We found that patients with mTOR mutations may tend to (P = 0.08) have a higher risk of death than patients without mTOR mutations while TNM stage and ulceration may definitely serve as independent prognostic factor for OS ( Table 3) .
Since mTOR activation may activate the downstream substrates eukaryotic initiation factor 4E (eIF4E) binding protein-1 (4EBP1) and p70 ribosomal protein S6 kinase 1 (p70S6K, which in turn phosphorylate the 40S ribosomal protein S6 (S6RP)) (15) . We examined the activation of these mTOR-associated molecules, including phospho-AKT, phospho-mTOR, phospho-S6RP and phospho-4EBP1 by immunohistochemistry (Supplementary Fig. S1 ). We found that the positive rate of phospho-AKT, phospho-mTOR and phospho-4EBP1 was not significantly different between melanomas bearing nonsynonymous mTOR mutations and those without nonsynonymous mTOR mutation. However, the positive rate for phospho-S6RP was significantly higher in melanomas bearing mTOR mutations than that in patients without nonsynonymous mTOR mutation (P = 0.004; Supplementary Table S5) .
Taken together the previous report that phospho-S6RP is positive in the majority of melanomas (29) , these data indicate that mTOR mutation may mainly affect the p70S6K-S6RP signaling pathway in melanoma.
We further analyzed the correlation between activation of mTOR-associated molecules and OS. We found that the survival times for patients negative or positive for phospho-AKT, phospho-mTOR, phospho-S6RP or phospho-4EBP1 were not significantly different (data not shown), indicating that activation of these mTOR-associated molecules may not predict prognosis in melanoma.
Functional analysis of mTOR mutations
To investigate whether the somatic nonsynonymous mutations of mTOR could activate mTOR/p70S6K pathway, 7 nonsynonymous mutants were overexpressed in HEK293T cells. Among the 7 mTOR mutations functionally examined, P1128L, V1275A, C1303R, T1830_T1834 [del] and G1914A were repeated mutations (2 cases for each mutation) while P2213S may affect the ATP pocket of kinase domain (30) . H1968Y was initially regarded as repeated mutation, which, however, was confirmed to be non-repeated after the functional assays in HEK293T cells in a later validation sequencing experiment. But H1968Y was shown in this study due to its gain-of-function mutation. The phosphorylation levels of endogenous p70S6K were analyzed by Western blotting following immunoprecipitations. Because S2215Y was previously demonstrated to be an activating mutation identified in large intestine adenocarcinoma (27) , it was used as the positive control. Strong phosphorylation of p70S6K was observed in H1968Y and P2213S mutants, whereas the other mutations showed weak to medium phosphorylation of p70S6K ( Fig. 2A and 2B ).
To further analyze the effects of mTOR mutants on downstream signaling pathway, we stably expressed mTOR mutants (C1303R and G1914A as non-functional mutation, and H1968Y and P2213S as functional mutation, and S2215Y as positive control) in HEK293T cells by TALEN. However, only H1968Y, P2213S and S2215Y cell clones were finally established. Function of mTOR mutants in these cells were analyzed by Western blotting. We found that the expression levels of mTOR (mutants) were equivalent between the established cells and wild type HEK293T cells (data not shown), indicating for the advantages of TALEN technique. But we found that phospho-p70S6K, phospho-4EBP1 and phospho-AKT were strongly detected in HEK293T cells with heterozygous or homozygous expression of H1968Y or P2213S mTOR mutants (Fig. 2C-2L) .
Therefore, H1968Y and P2213S mutations may be gain-of-function mutations.
Sensitivity of mTOR active mutations to PI3K-AKT-mTOR pathway inhibitors
To analyze the sensitivity of the gain-of-function mTOR mutations to PI3K-AKT-mTOR pathway inhibitors, HEK293T cells stably expressing H1968Y or P2213S mTOR mutants were treated with indicated inhibitors as described previously (31) (32) (33) (34) . The phosphorylation status of p70S6K, 4EBP1 and AKT was examined by Western blot under indicated drug concentrations. Phosphorylation levels of p70S6K, 4EBP1 and AKT induced by H1968Y, P2213S or S2215Y mutants were more significantly decreased by exposing to AZD5363 and LY294002 than BYL719 and Temsirolimus ( Fig. 3A and 3B ). For AZD5363, expression of phospho-AKT was more remarkably inhibited than phosho-p70S6K and phospho-4EBP1; For LY294002, levels of phospho-4EBP1 were more dramatically inhibited than p-p70S6K and phospho-AKT.
To confirm the effects of inhibitors on cells stably expressing active mTOR mutants, cell proliferation assays were performed. Consistent with the results of western blotting, proliferations of HEK293T cells stably expressing H1968Y, P2213S and S2215Y mTOR mutants were more significantly inhibited by AZD5363 and LY294002 than BYL719 and Temsirolimus (Fig. 3C-3J and Supplementary   Table S6 ). However, it should be noted that BYL719 and Temsirolimus did inhibit the cell proliferation at different concentrations, suggesting that these drugs were active but affected cell proliferation to similar extent between different strains of HEK293T cells. We also tested the other inhibitors, including Wortmannin, mutation frequency in CSD plus non-CSD melanomas is about 4.5% (4/88), which is similar to the TCGA and COSMIC data. This disparity may be due to the difference in melanoma subtypes. It should be noted that the frequency of mTOR mutations in acral and mucosal melanomas is about 12.1%, which is significantly higher than that in cutaneous melanomas. Therefore our study is of great significance for patients with acral or mucosal melanomas.
Thirty-five new types of nonsynonymous mutation have been identified in our study. The other six mutations have been reported by TCGA or COSMIC databases, with R311C, G716D, T1834_T1837del and R1811H identified in cancer samples, and with A1836T, A1134V and R1811H identified in tumor cell lines (22, 23, 46) .
We note that there are 12 cases of the detected 43 cases with mTOR nonsynonymous mutation showing signature of ultraviolet damage (C to T alteration), and two of them (C5902T for H1968Y, and C6637T for P2213S) were found to be gain-of-function mTOR mutation, indicating that ultraviolet damage may somehow be related to functional mutation of mTOR. However, this correlation may need to be supported by more data, such as analyzing the functional activity of all mTOR aberrations (identified in COSMIC and our study) with C to T nucleotide alteration. domain in regulating mTOR activity. With the advances of structural insights into mTOR and the advantages of TALEN, the effects of mTOR nonsynonymous mutations on regulation and activity of mTOR would be fully addressed in future studies. Since the nonsynonymous mutation of mTOR is rather variable and only 6 of them can be repeatedly detected, the relation of mTOR mutation to the activation of downstream signaling components in clinical samples could not be established at present. In our study, mTOR mutation could be concurrently detected in samples bearing BRAF, NRAS or CKIT mutation, which may raise the concern whether mTOR mutation may be related to clinical resistance to BRAF or MEK inhibitors.
One patient containing mTOR-A215S and BRAF-V600E mutation and treated with vemurafenib achieved partial response in our center, indicating that mTOR mutation may not affect response to these inhibitors. More studies are required to further clarify this concern.
Inhibitors targeting PI3K-AKT-mTOR signaling pathway have been clinically trialed in a panel of cancers. It may be expected that these inhibitors may also be beneficial for melanoma patients. However, phase II clinical trials in advanced melanomas have shown limited effects of mTOR inhibitors (20, 21) . Our study detected two new gain-of-function mutations of mTOR, that is, H1968Y and P2213S, in addition to S2215Y (27) . Our study suggests that these two mutations lead to activation of downstream signaling mediators, and they are sensitive to PI3K (LY294002 but not Wortmannin and BYL719) and AKT inhibitors (AZD5363 but Therefore the PI3K-AKT inhibitors may be more potent in inhibiting mTOR mutations and cell proliferation than the mTOR inhibitors. Further studies are required to functionally evaluate the other mTOR nonsynonymous mutations in melanomas and screen sensitive drugs for these mTOR mutants. However, our study at least identified two mTOR mutants that are sensitive to PI3K-AKT-mTOR pathway inhibitors, and melanoma patients bearing these two mutations may be candidates for targeted therapy using PI3K-AKT-mTOR pathway inhibitors.
Screening the patient population for specific biomarkers is useful to select proper patients for targeted therapy. Our study suggests that mTOR nonsynonymous mutation in melanoma patients is rather frequent (10.3%) and mTOR may thus be a potential target for targeted therapy in Asian melanoma patients. Since only a portion of patients are sensitive to PI3K-AKT-mTOR inhibitors, it should be cautious to select candidates for clinical trials.
